Physician profile
Pablo Feuillet
NPI 1922052570
$9,544.92
in general payments reported to CMS, 2019-2025
18 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,832 · 2020: $1,677 · 2021: $462 · 2022: $115 · 2023: $34.35 · 2024: $146 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $4,561.56 | 2019-2022 | |
| Allergan, INC. | $1,741.58 | 2019-2020 | |
| Cipla USA INC. | $1,439.23 | 2020-2021 | |
| Viiv Healthcare Company | $565.61 | 2019-2024 | Cabenuva, Dovato |
| Merck Sharp & Dohme LLC | $315.64 | 2019-2024 | Recarbrio, Dificid, Zerbaxa |
| Cumberland Pharmaceuticals, INC. | $174.11 | 2019-2020 | |
| Atricure, INC. | $155.74 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Paratek Pharmaceuticals, INC. | $123.10 | 2025 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $116.57 | 2019 | |
| Abbvie INC. | $74.44 | 2022-2024 | |
| Astellas Pharma US INC | $30.36 | 2024 | Cresemba |
| Alexion Pharmaceuticals, INC. | $30.00 | 2019 | |
| Perspectum Diagnostics LTD | $25.87 | 2022 | |
| Ferring Pharmaceuticals INC. | $20.45 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $18.72 | 2023 | Xarelto |
| Mayne Pharma Commercial LLC | $14.53 | 2019 | |
| Theratechnologies INC. | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Feuillet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.